CONNECT WITH US
HealthTech

HealthTech

HIV drug lenacapavir found to disrupt virus formation, creating giant noninfectious particles

Medical Xpress logo

Published on

Add as a preferred source on Google
HIV drug lenacapavir found to disrupt virus formation, creating giant noninfectious particles

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Lenacapavir is a powerful, long-acting drug used to prevent and treat HIV infection. While it is known to block key steps in the virus's replication after entering a cell, researchers have now uncovered another way the drug works: it disrupts the formation of new virus particles, causing them to become abnormally large and noninfectious.

The study, published in Proceedings of the National Academy of Sciences, was conducted through a collaboration involving Kumamoto University, Hamamatsu University School of Medicine, the University of Miyazaki, the National Hospital Organization Nagoya Medical Center and Tokyo University of Technology.

Led by lecturer Kazuaki Monde of Kumamoto University and Professor Yasumasa Iwatani of Hamamatsu University School of Medicine, the research team investigated how lenacapavir affects HIV-1 during the late stages of its life cycle, when new virus particles are assembled and released from infected cells.

The researchers found that lenacapavir binds not only to the mature capsid protein but also to its precursor, a protein called Gag, which helps build new virus particles. This interaction disrupts normal particle assembly and promotes the formation of unusually large virus-like particles measuring more than 200 nanometers in diameter—considerably larger than typical HIV particles, which are generally around 100–130 nanometers.

"An important and unexpected finding of our study is that lenacapavir can bind to both precursor Gag and mature Gag, despite differences in their structures and assembly states," said Monde.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.